1. Kumar, A., Kumar, V., Shukla, G.C., and Rao, K.V., Immunological characteristics of a recombinant Hepatitis B virus derived multiple-epitope polypeptide: a study in polyvalent vaccine design. Vaccine; 1994, 12(3): 259-66.
2. Shukla, G.C. and Nene, V., Telomeric features of Theileria parva mitochondrial DNA derived from cycle sequence data of total genomic DNA. Mol. Biochem. Parasitol. 1998, 95, 159-163.
3. Shukla, G.C. and Padgett, R.A. Features of U6atac and U12 snRNA are conserved in plants and higher organisms RNA, 1999, 5:525-538.
4. Shukla, G.C. and Padgett, R.A. The intramolecular stem-loop of U6 snRNA can functionally replace the U6atac snRNA stem-loop. RNA, 2001, 7:94-105.
5. Dietrich, R.C., Shukla, G.C., Fuller, J. D., and Padgett, R.A. Alternative splicing of U12-dependent introns in vivo responds to purine-rich enhancers RNA, 2001, 7:1378-1388.
6. Padgett, R.A. and Shukla, G.C. A revised model for U4atac/U6atac snRNA base pairing. RNA, 2002, 8:1-4.
7. Shukla, G.C., and Padgett R.A. A catalytically competent group II intron domain 5 can functionally replace the spliceosomal U6atac snRNA stem-loop Mol. Cell 2002, 9:1145-1150.
8. Shukla, G.C., and Padgett, R.A. U4 small nuclear RNA can function in both the major and minor spliceosomes Proc. Natl. Acad. Sci., 2004, 6, 101 (1): 93-98.
9. Shukla, G.C., Cole, A. Dietrich, R.A. and Padgett, R.A. Domains of human U4atac snRNA required for U12-dependent splicing in vivo Nucl. Acid Res., 2002, 30, 21: 4650-4657.
10. Dietrich RC, Padgett RA, Shukla GC*. The conserved 3' end domain of U6atac snRNA can direct U6 snRNA to the minor spliceosome. RNA. 2009 Jun;15(6):1198-207.
11. Sikand K, Slane SD, Shukla GC*. Intrinsic expression of host genes and intronic miRNAs in prostate carcinoma cells. Cancer Cell Int. 2009 Aug 12;9(1):21.
12. Sikand K, Shukla GC. Functionally important structural elements of U12 snRNA. Nucleic Acids Res. 2011 Oct;39(19):8531-43. Epub 2011 Jul 6. PubMed PMID: 21737423; PubMed Central PMCID: PMC3201867.
13. Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC. miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer. 2011 Aug 5;129(4):810-9. doi: 10.1002/ijc.25753. PubMed PMID: 21710544.
14. Shukla GC, Haque F, Tor Y, Wilhelmsson LM, Toulmé JJ, Isambert H, Guo P, Rossi JJ, Tenenbaum SA, Shapiro BA. A boost for the emerging field of RNA nanotechnology. ACS Nano. 2011 May 24;5(5):3405-18. PubMed PMID: 21604810; PubMed Central PMCID: PMC3102291.
15. Sikand K, Barik S, Shukla GC. MicroRNAs and Androgen Receptor 3' Untranslated Region: A Missing Link in Castration-resistant Prostate Cancer? Mol Cell Pharmacol. 2011;3(3):107-113. PubMed PMID: 22468168; PubMed Central PMCID: PMC3315684.
16. Shukla GC, Singh J, Barik S. MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol. 2011;3(3):83-92. PubMed PMID: 22468167; PubMed Central PMCID: PMC3315687.
17. Sikand K, Singh J, Ebron JS, Shukla GC. Housekeeping Gene Selection Advisory: Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) and ß-Actin Are Targets of miR-644a. PLoS One. 2012;7(10):e47510. doi: 10.1371/journal.pone.0047510. Epub 2012 Oct 16. PubMed PMID: 23091630; PubMed Central PMCID: PMC3472982.
18. Ebron JS, Weyman C, Shukla GC. Targeting of Androgen Receptor expression by andro-miRs as novel adjunctive therapeutics in Prostate Cancer, Journal of Cancer Therapy, 2013.
19. Singh G, Shukla GC, Gupta S. MicroRNA regulating Glutathione S-transferase P1 in Prostate Cancer, Curr Pharmacol Rep, 2015.
20. Al-Harbi S, Choudhary GS, Ebron JS, Hill BT, Vivekanathan N, Ting AH, Radivoyevitch T, Smith MR, Shukla GC, Almasan A. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. Mol Cancer. 2015 Nov 4;14(1):185. doi: 10.1186/s12943-015-0460-8. PubMed PMID: 26537004; PubMed Central PMCID: PMC4632834.
21. Singh S, Zheng Y, Jagadeeswaran G, Ebron JS, Sikand K, Gupta S, Sunker R, Shukla GC. Deep sequencing of small RNA libraries from human prostate epithelial and stromal cells reveal distinct pattern of microRNAs primarily predicted to target growth factors. Cancer Lett. 2016 Feb 28;371(2):262-73. doi:  0.1016/j.canlet.2015.10.038. Epub 2015 Dec 3. PubMed PMID: 26655274.
22. Ebron JS, Shukla GC. Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region. Prostate. 2016 Mar 14. doi: 10.1002/pros.23174. [Epub ahead of print] PubMed PMID: 26988939.
23. Shukla GC, Plaga AR, Shankar E, Gupta S. Androgen receptor-related diseases: what do we know? Andrology. 2016 Mar 16. doi: 10.1111/andr.12167. [Epub ahead of print] Review. PubMed PMID: 26991422.
24. Singh J, Sikand K, Conrad H, Will CL, Komar AA, Shukla GC. U6atac snRNA stem-loop interacts with U12 p65 RNA binding protein and is functionally interchangeable with the U12 apical stem-loop III. Sci Rep. 2016 Aug 11;6:31393.  doi: 10.1038/srep31393. PubMed PMID: 27510544; PubMed Central PMCID: PMC4980772.
25. Singh S, Plaga A and Shukla GC. Racial Disparities: Disruptive genes in prostate carcinogenesis. Frontiers of Biosciences 9;244-253, June 1, 2017.
26. Makwana K, Patel SA, Velingkaar N, Ebron JS, Shukla GC, Kondratov RVKV. Aging and calorie restriction regulate the expression of miR-125a-5p and its target genes Stat3, Casp2 and Stard13. Aging (Albany NY). 2017 Jul 31;9(7):1825-1843. doi: 10.18632/aging.101270. PubMed PMID: 28783714.
27. Zheng Y, Liu L, and Shukla GC. A comprehensive review of web-based non-coding RNA resources for cancer research. Cancer Lett. 2017 Aug 18;407:1-8. doi: 10.1016/j.canlet.2017.08.015. [Epub ahead of print]PMID:28823961
28. Shukla GC and Singh S. Mutations of RNA splicing factors in hematological cancers. Cancer Lett. 2017 Sep 6. pii: S0304-3835(17)30537-2. doi: 10.1016/j.canlet.2017.08.042. [Epub ahead of print] PMID:28888996
29. Fnu, R., Plaga, A., Eswar Shakar, Shukla GC, Gupta S. MicroRNAs in prostate cancer: Functional role as biomarker. Cancer Lett. 2017 Aug 18;407:9-20. doi: 10.1016/j.canlet.2017.08.011. [Epub ahead of print] PMID:28823964
30. Jey Sabith Ebron , Eswar Shankar, Jagjit Singh, Kavleen Sikand, Crystal M Weyman, Sanjay Gupta, Daniel J. Lindner, Xiaoqi Liu, Moray J. Campbell, and Shukla GC MicroRNA-644a disrupts oncogenic transformation in prostate cancer by regulating the androgen signaling, Warburg effect and other tumor promoting pathways (submitted for peer-review).
31. Terri J Harford, Greg Kliment, Shukla GC and Crystal Weyman. The muscle regulatory transcription factor MyoD participates with p53 to directly increase the expression of the pro-apoptotic Bcl2 family member PUMA. 2017 Dec;22(12):1532-1542. doi: 10.1007/s10495-017-1423-x. PMID: 28918507
32. Shukla GC, Gupta S. RNA biology-featuring the special issue guest editors "cancer letters". Cancer Lett. 2018 Feb 13;421:41-42. doi: 10.1016/j.canlet.2018.01.077. [Epub ahead of print] PubMed PMID: 29452145.
33. 2: Shukla GC, Gupta S. Hallmarks of cancer- focus on RNA metabolism and regulatory noncoding RNAs. Cancer Lett. 2018 Apr 28;420:208-209. doi: 10.1016/j.canlet.2018.01.063. Epub 2018 Feb 2. PubMed PMID: 29409790.